The coexistence of type 2 diabetes and obesity represents a major global health challenge that significantly increases cardiovascular and metabolic risk.

Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, researchers aren’t giving up yet.

Regular exercise and sufficient protein intake can help maintain muscle and preserve long-term health in patients taking GLP-1 receptor agonists.

GLP-1 RAs are safe and efficacious for adults with IBD, with no increased risk for flare-ups, hospitalization, corticosteroid use, or operation.

The new World Health Organization guideline supports using GLP-1 drugs for long-term obesity care, emphasizing lifestyle, behavioral therapy.

Researchers have developed a new oral drug that boosts metabolic activity in muscle rather than altering appetite like GLP-1 ...

FGF19 triggers the brain to burn more energy and activate fat-burning cells, offering a potential new path for obesity ...

A California company, Okava Pharmaceuticals, has launched a clinical trial testing a GLP-1–based weight loss treatment in 50 ...

RNA-based therapeutics face challenges in bioanalysis, with experts recommending strategies to improve LC–MS performance and standardize ADME and DMPK practices. GLP-1 therapies require careful ...

A new study suggests Korea’s iconic fermented dish, kimchi, may do more than enrich the gut — it could strengthen the immune ...

Dietitian Live has mapped a repeatable subconscious-to-physiology pathway showing that when belief shifts, the body heals. The company uncovered a consistent, client-partnered process for rewiring ...

A first-of-its-kind oral drug boosts muscle metabolism to improve blood sugar and body composition is now headed into larger clinical trials. Lowering blood sugar and increasing fat burning – without ...